documents incorporated reference incorporated scheringplough corporation parts ii iv annual report shareholdersscheringplough corporation proxy part iii statement annual meeting shareholders april part item business terms scheringplough company used herein refer scheringplough corporation subsidiaries except otherwise indicated context scheringplough corporation holding company incorporated trademarks indicated capital letters property licensed promoted distributed scheringplough corporation subsidiaries related companies subsidiaries scheringplough engaged discovery development manufacturing marketing pharmaceutical products worldwide discovery development efforts target field human health occasionally applications field animal health result efforts company views animal health applications means maximize return investments discovery development company operates primarily prescription pharmaceutical marketplace however appropriate company sought may future seek regulatory approval switch prescription products overthecounter otc status means extending product 's life cycle way otc marketplace yet another means maximizing return investments discovery development prescription product sales include allergy products claritin loratadine claritin claritin syrup claritin prescription sales united states formulations accounted percent company 's consolidated worldwide sales percent larger percentage company 's consolidated earnings march company announced us food drug administration fda accepted company 's application switch indications claritin otc products november company announced fda approved five formulations claritin original prescription strengths otc medicines treatment allergies company began shipping otc claritin december united states company continues market clarinex desloratadine mg tablets treatment allergic rhinitis combines indication seasonal allergic rhinitis indication perennial allergic rhinitis well treatment chronic idiopathic urticaria hives unknown cause ability company capture maintain market share clarinex otc claritin us market depend number factors including additional entrants market allergy treatments clinical differentiation clarinex allergy treatments perception extent differentiation marketplace pricing differentials among otc claritin clarinex allergy treatments generic otc loratadine erosion rate otc claritin clarinex sales upon entry additional generic otc loratadine products whether one branded secondgeneration antihistamines switched prescription otc status switch claritin otc status resulted rapid sharp material decline claritin sales united states us sales claritin prescription products billion billion respectively percent percent respectively company 's consolidated worldwide sales years worldwide sales clarinex launched united states january million sales clarinex united states abroad could also materially adversely affected presence generic otc loratadine otc claritin market given anticipated contraction prescription antihistamine market light factors described management believes company 's december introduction otc claritin well introduction competing otc loratadine product december additional entrants generic otc loratadine products market likely rapid sharp material adverse effect company 's results operations indeterminate period time may company merck co inc merck entered agreements jointly develop market united states new prescription medicines cholesterolmanagement respiratory therapeutic areas agreements cover development marketing coadministration zetia ezetimibe company 's novel cholesterol absorption inhibitor statins zetia oncedaily monotherapy ezetimibe oncedaily fixedcombination tablet simvastatin zocor merck 's cholesterolmodifying medicine oncedaily fixedcombination tablet containing claritin singulair treatment allergic rhinitis asthma singulair merck 's oncedaily leukotriene receptor antagonist treatment asthmain december cholesterolmanagement agreements expanded include countries world except japan january scheringploughmerck pharmaceuticals reported results phase iii clinical trials fixedcombination tablet containing claritin singulair demonstrate sufficient added benefits treatment seasonal allergic rhinitis october ezetimibe approved sale germany marketed ezetrol also october fda approved zetia use either together statins patients high cholesterol reduce ldlc bad cholesterol total cholesterol agreements companies generally provide equal sharing development costs copromotion approved products company united states countries world except japan japan agreement exists general copromotion provides company provide equal physician detailing efforts bear cost sales force marketing products companies share certain costs eg portion costs manufacturing promotion administration etc also share profits agreements provide jointly owned facilities products resulting collaboration manufactured facilities owned either merck company additional prescription products sold company include celestamine nasonex polaramine proventil allergyrespiratory caelyx cedax eulexin garamycin intron pegintron rebetol ribavirin remicade temodar antiinfective anticancer diprolene diprosone elocon lotrisone quadriderm valisone dermatologicals integrilin kdur nitrodur cardiovasculars celestone diprospan subutex pharmaceuticals pegintron rebetol combination therapy hepatitis c contributed substantially sales fourth quarter competing pegylated interferonbased combination product including brand ribavirin received regulatory approval major markets including united states management believes ability pegintron rebetol combination therapy maintain market share adversely affected introduction competing product animal health products include cepravin nuflor antimicrobials banamine nonsteroidal antiinflammatory ralgro growth promotant implant otomax otic product broad range vaccines many species parasiticides sutures bandages nutritional products foot care otc sun care products include clear away wart remover dr scholl 's foot care products lotrimin tinactin antifungals ointment afrin nasal decongestant chlortrimeton antihistamine claritin allergy coricidin drixoral cold decongestant products correctol laxative bain de soleil coppertone solarcaine sun care products net sales major product therapeutic category dollars millions years ended december percent change allergy respiratory clarinex nm claritin rx nasonex proventil allergy respiratory antiinfective anticancer intron franchise remicade nm temodar antiinfective anticancer cardiovasculars integrilin kdur nitrodur cardiovasculars dermatologicals pharmaceuticals worldwide pharmaceuticals animal health foot care otc otc claritin nm otc sun care consolidated net sales certain sales amounts reclassified selling general administrative expenses net sales comply eitf issue vendor income statement characterization consideration paid reseller vendor 's products nm meaningful sales clarinex launched international markets included claritin rx sales intron franchise consists intron pegintron rebetol segment information set forth pages notes consolidated financial statements company 's annual report shareholders incorporated herein reference prescription drugs introduced made known physicians pharmacists hospitals managed care organizations buying groups trained professional sales representatives sold hospitals certain managed care organizations wholesale distributors retail pharmacists prescription products also introduced made known journal advertising direct mail advertising distributing samples physicians television radio internet print advertising media animal health products promoted veterinarians distributors animal producers foot care otc sun care products sold wholesale retail drug food chain mass merchandiser outlets promoted directly consumer television radio internet print advertising media pharmaceutical industry highly competitive includes large companies substantial resources research product development advertising promotion field selling support numerous domestic international competitors industry principal competitive techniques used company products include research development new improved products high product quality varied dosage forms strengths switching prescription products nonprescription status united states many company 's products subject increasingly competitive pricing managed care groups institutions federal state government entities agencies buying groups seek price discounts rebates governmental pressures toward dispensing generic products may significantly reduce sales certain products become longer protected patents data exclusivity arrangements fda company 's subsidiaries licensed rights number patents patent applications united states abroad patents patent applications relating company 's significant products including without limitation clarinex claritin family products intron pegintron rebetol nasonex zetia materialimportance company compound patent loratadine expired june us market exclusivity claritin expired december patent covering compound desloratadine formulations thereof methods treatment desloratadine relates claritin set expire april six months ' us market exclusivity would attach end desloratadine patent relates claritin would expire october sixmonth period exclusivity granted company conducted pediatric clinical trials request fda patents subject litigation described item legal proceedings worldwide company 's products sold trademarks trademarks considered aggregate material importance business protected registration common law united states markets products sold raw materials essential company available adequate quantities number potential suppliers energy expected available company sufficient quantities meet operating requirements seasonal patterns pronounced effect consolidated operations company percent percent percent respectively consolidated net sales made mckesson corporation major pharmaceutical health care products distributor also percent percent percent respectively consolidated net sales made amerisourcebergen corporation major pharmaceutical health care products distributor substantially sales united states foreign operations foreign activities carried primarily whollyowned subsidiaries wherever market potential adequate circumstances permit addition company represented markets licensees distribution arrangements approximately employees outside united states foreign operations subject certain risks inherent conducting business overseas risks include possible nationalization expropriation importation limitations pricing restrictions restrictive governmental actions economic destabilization also fluctuations foreign currency exchange rates impact company 's consolidated financial results additional information foreign operations see management 's discussion analysis operations financial condition segment information beginning pages respectively company 's annual report shareholders incorporated herein reference research development company 's research activities primarily aimed discovering developing new enhanced prescription products medical commercial significance company sponsored research development expenditures million million million respectively research expenditures represented approximately percent consolidated net sales approximately percent consolidated net sales approximately percent consolidated net sales company 's research activities concentrated therapeutic areas allergic inflammatory disorders infectious diseases oncology cardiovascular diseases central nervous system disorders company also substantial efforts directed toward biotechnology gene therapy immunology research activities include expenditures internal research efforts research collaborations various partners several pharmaceutical compounds varying stages development predicted compounds become available commercial sale government regulation pharmaceutical companies subject extensive regulation number national state local agencies particular importance fda jurisdiction company 's businesses administers requirements covering testing approval safety effectiveness manufacturing labeling marketing company 's products extent fda requirements andor reviews affects amount resources necessary develop new products bring market united states ongoing basis fda regulates facilities procedures used manufacture pharmaceutical products united states sale united states products made facilities manufactured accordance good manufacturing practices gmps established fda fda periodically inspects company 's facilities procedures evaluate compliance december company announced negotiations fda enter consent decree resolve issues involving company 's compliance current gmps certain manufacturing facilities new jersey puerto rico may company announced reached agreement fda consent decree resolve issues us district court district new jersey approved consent decree terms consent decree company pay total million us government two equal installments million first installment paid may second installment paid second quarter previously reported company accrued million provision consent decree fourth quarter event certain actions agreed upon consent decree satisfactorily completed time fda may assess payments deadline missed payments may exceed million million years payments subject overall cap million company scheduled complete revalidation plans december general addition payments described product scheduled revalidation certification consent decree certified within six months scheduled date company must cease production product certification obtained product scheduled revalidation certification certified validated last date validation schedule currently december finished drugs september bulk active pharmaceutical ingredients fda may assess payment percent net domestic sales uncertified product validation certified company would expense payments incurred connection agreement company decided discontinue manufacturing marketing certain older products consent decree also includes recall initiated early may directed us trade accounts lots theophylline usp tablets proventil albuterol sulfate usp repetabs proventil inhalers affected recall company discontinued marketing us theophylline products june proventil repetabs available since july total products represented annual sales approximately million company recalled certain sterile human animal drug products manufactured manati puerto rico facility financial impact recalls immaterial failure comply governmental regulations result delays release products delays approvals new products seizure recall products suspension revocation authority necessary production sale products fines civil criminal sanctions fda also regulates conversion pharmaceuticals prescription otc status company 's activities outside united states also subject regulatory requirements governing testing approval safety effectiveness manufacturing labeling marketing company 's products regulatory requirements vary country country whether fda approval approval european medicines evaluation agency obtained product approval product comparable regulatory authorities countries outside united states european union case may must obtained prior marketing product countries approval process may less rigorous country country time required approval may longer shorter required united states approval one country assure product approved another country international markets company operates environment governmentmandated costcontainment programs several governments placed restrictions physician prescription levels patient reimbursements emphasized greater use generic drugs enacted acrosstheboard price cuts methods cost control recent years various legislative proposals offered congress many state legislatures would effect major changes affected health care systems one change could material company possible addition outpatient prescription drug benefit medicare states passed legislation federal state legislative administrative proposals possible could include price patient reimbursement constraints medicines mandated discounts supplemental rebates expansion existing governmental programs new patient populations restrictions access certain products similar issues also arisen many countries outside united states possible predict outcome initiatives effect operations cash flows reasonably estimated company also subject jurisdiction various federal state regulatory enforcement departments agencies federal trade commission ftc department justice department health human services united states company therefore subject possible administrative legal proceedings actions organizations actions may result imposition civil criminal sanctions may include fines penalties injunctive administrative remedies environment date compliance federal state local environmental protection laws materially adverse effect company company made continue make necessary expenditures environmental protection worldwide capital expenditures included approximately million environmental control purposes anticipated continued compliance environmental regulations significantly affect company 's financial statements competitive position additional information environmental matters see legal environmental regulatory matters beginning notes consolidated financial statements company 's annual report shareholders incorporated herein reference employees approximately people employed company december available information company makes annual report quarterly reports form q current reports form k amendments reports filed sec available free charge web site soon reasonably practicableafter materials electronically filed sec company 's address world wide web schering ploughcom since company began practice third quarter report available company 's web site within hours filing cautionary factors may affect future results cautionary statements private securities litigation reform act report written reports oral statements made time time company may contain socalled forwardlooking statements subject risks uncertainties one often identify forwardlooking statements use words expects plans estimates forecasts projects believes anticipates words similar meaning one also identify fact relate strictly historical current facts statements likely address company 's growth strategy financial results regulatory issues status product approvals development programs litigation investigations one must carefully consider statement understand many factors could cause actual results differ company 's forwardlooking statements factors include inaccurate assumptions broad variety risks uncertainties including known forwardlooking statement guaranteed actual future results may vary materially company assume obligation update forwardlooking statement although possible predict identify factors may include following significant portion net sales made major pharmaceutical health care products distributors major retail chains united states consequently net sales quarterly growth comparisons may affected fluctuations buying patterns major distributors retail chains trade buyers fluctuations may result seasonality pricing wholesaler buying decisions factors competitive factors including technological advances attained competitors patents granted competitors new products competitors coming market new indications competitive products generic prescription otc competition company 's products mature patents expire products increased pricing pressure united states abroad managed care organizations institutions government agencies programs united states among developments consolidation among customers may increase pricing pressures may result various customers greater influence prescription decisions formulary decisions policies government laws regulations changes laws regulations affecting domestic international operations enforcement thereof including among laws regulations resulting healthcare reform initiatives united states state federal level countries well laws regulations relating trade antitrust monetary fiscal policies taxes price controls possible nationalization patent positions highly uncertain patent disputes unusual adverse result patent dispute preclude commercialization products negatively impact sales existing products result injunctive relief payment financial remedies uncertainties fda approval process regulatory approval processes nonus countries including without limitation delays approval new products failure meet gmps established fda governmental authorities result delays release products seizure recall products suspension revocation authority necessary production sale products fines civil criminal sanctions resolution manufacturing issues fda discussed report subject substantial risks uncertainties risks uncertainties including timing scope duration resolution manufacturing issues depend ability company assure fda quality reliability manufacturing systems controls extent remedial prospective obligations undertaken company difficulties product development pharmaceutical product development highly uncertain products appear promising development may fail reach market numerous reasons may found ineffective harmful side effects clinical preclinical testing may fail receive necessary regulatory approvals may turn economically feasible manufacturing costs factors may precluded commercialization proprietary rights others efficacy safety concerns respect marketed products whether scientifically justified leading recalls withdrawals declining sales major products claritin clarinex intron pegintron rebetol capsules nasonex accounted material portion company 's revenues major product become subject problem loss patent protection otc availability indicated claritin current potential otc competition previously unknown side effects new effective treatment introduced product discontinued reason impact revenues could significant legal factors including product liability claims litigation government investigations patent disputes withcompetitors environmental concerns could preclude commercialization products negatively affect profitability existing products economic factors company control including changes inflation interest rates foreign currency exchange rates changes tax laws including changes related taxation foreign earnings changes accounting standards promulgated american institute certified public accountants financial accounting standards board securities exchange commission adverse company item properties company 's corporate headquarters located kenilworth new jersey principal manufacturing facilities located kenilworth new jersey miami florida omaha nebraska cleveland tennessee puerto rico argentina belgium canada france germany ireland italy japan mexico singapore spain company 's principal research facilities located kenilworth union new jersey palo alto san diego california elkhorn nebraska may company announced reached agreement fda enter consent decree resolve issues involving company 's compliance current gmps certain manufacturing facilities new jersey puerto rico refer government regulation section within item additional information regarding consent decree major portion properties owned company properties generally well maintained adequately insured generally good operating condition company 's manufacturing facilities capacities considered appropriate meet company 's needs item legal proceedings background company responsibilities environmental cleanup various state local federal laws including comprehensive environmental response compensation liability act commonly known superfund several superfund sites equivalent sites state law company alleged potentially responsible party prp company estimates obligations cleanup costs superfund sites based information obtained federal environmental protection agency equivalent state agency andor studies prepared independent engineers probable costs paid prps company records liability environmental assessments andor cleanup probable loss incurred amount reasonably estimated company also involved various claims legal proceedings nature considered normal business including product liability cases company adjusts accrued liabilities reflect current best estimate probable loss exposure best estimate determinable company accrues minimum amount within probable range liability recorded liabilities matters december related expenses incurred year ended december material expected insurance recoveries considered determining costs environmentalrelated liabilities management believes except matters discussed remainder section remote material liability excess amounts accrued incurred respect matters discussed remainder section except noted practicable estimate range reasonably possible loss reserve included financial statements resolution matters discussed remainder section individually aggregate could material adverse effect company 's results operations financial condition management reviews status matters ongoing basis time time may settle otherwise resolve terms conditions management believes best interests company company aware settlements matters types set forth remainder section particular investigations frequently involve fines andor penalties material financial condition results operations entity entering settlement assurances company prevail matters settlements reached acceptable terms amounts exceed amounts reserved outcomes predicted environmental residents vicinity publicly owned wastewater treatment plant barceloneta puerto rico filed two lawsuits plant owner operator numerous companies discharge plant including subsidiary company damages injunctive relief relating odors allegedly coming plant connecting sewers one lawsuits class action claiming damages million discovery ongoing lawsuits patent mattersin february geneva pharmaceuticals inc geneva submitted abbreviated new drug application anda us fda seeking market generic claritin tablets expiration company 's desloratadine compound patent company believes protects claritin geneva alleged desloratadine compound patent invalid patent material company 's business march company filed suit federal court seeking ruling geneva 's anda submission constitutes infringement company 's desloratadine compound patent challenge patent without merit addition geneva following companies made similar anda submissions generic claritin tablets zenith goldline pharmaceuticals mylan pharmaceuticals inc teva pharmaceuticals usa inc teva ranbaxy pharmaceuticals inc genpharm incorporated l perrigo company perrigo following companies made similar anda submissions generic claritin syrup teva copley pharmaceuticals inc novex pharma alpharma uspd inc taro pharmaceuticals usa inc morton grove pharmaceuticals inc perrigo andrx pharmaceuticals llc andrx impax laboratories inc impax made similar anda submissions generic claritind hour claritind hour formulations esi lederle inc lederle subsidiary wyeth made similar anda submission generic claritin reditab formulation following companies submitted paper new drug applications paper ndas section b federal food drug cosmetic act seeking market generic otc form claritin prior expiration company 's desloratadine compound patent whitehallrobins healthcare division wyeth otc reditab formulation mcneil consumer healthcare mcneil otc tablets perrigo otc tablets case company filed suit federal court seeking ruling applicable anda paper nda submission proposed marketing generic prescription otc product constitutes infringement company 's desloratadine compound patent challenge patent without merit august federal district court new jersey ruled motions summary judgment finding certain claims desloratadine compound patent anticipated prior patent thus valid september district court denied request reconsideration company appealed rulings appeal scheduled argued april company anticipates appeal decided second half early rulings actions defendants infringement desloratadine compound patent proceed unless company 's appeal successful company also asserted impax 's andrx 's andas generic claritind hour formulations infringe company 's patent covering claritind hour formulation issue yet resolved district court august geneva pharmaceuticals technology corp geneva pharmaceuticals three rivers pharmaceuticals llc three rivers january teva submitted separate andas fda seeking market generic forms mg rebetol ribavirin capsules united states expiration company 's patents covering ribavirin formulations geneva pharmaceuticals three rivers teva asserted infringe company 's rebetol patents andor patents invalid rebetol patents material company 's business september october march company filed suits federal court seeking rulings anda submissions geneva pharmaceuticals three rivers teva respectively constitute infringement company 's patents challenges company 's patents without merit february company entered licensing agreement three rivers settle patent litigation company three rivers terms agreement company grant three rivers nonexclusive nonsublicensable license company 's us ribavirin patents three rivers pay company royalty ribavirin sales agreement affect three rivers ' reported patent litigation ribapharm inc agreement subject dismissal relevant lawsuits court patent litigation geneva teva temporarily stayed parties seek reach settlement january jury found company 's prime pac prrs porcine respiratory reproductive syndrome vaccine infringed patent owned boehringer ingelheim vetmedica inc injunction issued august barring sales company 's vaccine company 's posttrial motions either reversal jury 's verdict new trial denied september company appealed verdict affirmed appellate court february discovery damages phase case ongoing investigations october company received subpoena us attorney 's office eastern district pennsylvania pursuant health insurance portability accountability act concerning company 's contracts pharmacy benefit managers pbms managed care organizations provide disease management services connection marketing pharmaceutical products appears subpoena one number addressed industry participants part inquiry among things pharmaceutical marketing practices government 's inquiry focused among things whether company 's disease management marketing programs arrangements comply federal health care laws whether value disease management programs marketing programs arrangements included calculation rebates government company cooperating investigation march us attorney 's office began issuing grand jury subpoenas grand jury investigation appears focused one transactions managed care organizations government believes company offered provided deeply discounted pharmaceutical products known nominally priced products generally excluded medicaid rebate calculations free discounted disease management services marketing programs arrangements delivered value order place retain one company 's major pharmaceutical products managed care organization 's formulary grand jury appears investigating among things whether transactions described conduct relating thereto violated federal antikickback statutes ii whether value items services described included company 's calculation medicaid rebates outcome investigations could include commencement civil andor criminal proceedings involving substantial fines penalties injunctive administrative remedies including exclusion government reimbursement programs company predict whether investigations affect marketing practices sales february company increased litigation reserves related investigation investigations described theus attorney 's office district massachusetts million increased litigation reserves reflect adjustment company 's estimate minimum liability relating investigations compliance generally accepted accounting principles gaap gaap companies required estimate recognize minimum liability loss probable better estimate loss made also gaap company required recognize liability company notes total reserves reflect estimate final settlement adjudication matters could possibly less could materially exceed aggregate liability accrued company could materially adverse effect operations financial condition company adjustment consistent company 's policy reviewing regularly status pending actions investigations making adjustments appropriate company responding investigations department health human services department justice certain states certain industry company practices regarding average wholesale price awp investigations include department justice review merits federal action filed private entity behalf united states us district court southern district florida well investigation us attorney 's office district massachusetts regarding inter alia whether awp set pharmaceutical companies certain drugs improperly exceeds average prices paid dispensers consequence results unlawful inflation certain government drug reimbursements based awp march company received subpoena massachusetts attorney general 's office seeking documents concerning use awp pricing andor marketing practices company cooperating investigations outcome investigations could include imposition substantial fines penalties injunctive administrative remedies us attorney 's office district massachusetts also investigating whether company 's sales product repackaged sale managed care organization included company 's medicaid best price calculations early november company served two additional grand jury subpoenas us attorney district massachusetts among information subpoenas seek broad range information concerning company 's sales marketing clinical trial practices programs respect intron rebetron temodar company 's sales marketing contacts managed care organizations doctors company 's offering provision grants honorariums items services value managed care organizations physician groups doctors educational institutions company understands investigation focused whether certain sales marketing clinical trial practices conduct related thereto certain instances relate use one mentioned products indications fda approval obtained socalled offlabel uses violation federal laws regulations respect offlabel promotional activities investigation also appears focus whether drug samples clinical trial grants items services value given providers incentivize prescribe one abovementioned products including offlabel uses violation federal health care anti kickback laws company implemented certain changes sales marketing clinical trial practices continuing review practices ensure compliance relevant laws regulations company cooperating investigations future sales intron rebetron temodar may adversely affected company time predict ultimate impact sales outcome investigations could include commencement civil andor criminal proceedings involving imposition substantial fines penalties injunctive administrative remedies including exclusion government reimbursement programs february company increased litigation reserves related investigations us attorney 's office district massachusetts described paragraph paragraph immediately preceding investigation described us attorney 's office eastern district pennsylvania million increased litigation reserves reflect adjustment company 's estimate minimum liability relating investigations compliance gaap gaap companies required estimate recognize minimum liability loss probable better estimate loss made also gaap company required recognize liability company notes total reserves reflect estimate final settlement adjudication matters could possibly less could materially exceed aggregate liability accrued company could materially adverse effect operations financial condition company adjustment consistent company 's policy reviewing regularly status pending actions investigations making adjustments appropriate us attorney 's office new jersey along fda 's office criminal investigation conducting investigation may focus one company products including ribavirin manufactured puerto rico company cooperating government investigation us department justice antitrust division investigating whether company 's consumer products division entered agreement another company lower commission rate consumer products broker february antitrust division served grand jury subpoena company seeking documents first time company cooperating investigation securities class action litigation february company stated press release fda conducting inspections company 's manufacturing facilities new jersey puerto rico issued reports citing deficiencies concerning compliance current good manufacturing practices primarily relating production processes controls procedures next day february lawsuit filed us district court district new jersey company certain named officers alleging violations sections b securities exchange act rule bpromulgated thereunder additional lawsuits tenor followed plaintiffs suits purport represent classes shareholders purchased shares company stock dates early march february date press release april lawsuit filed us district court district new jersey company certain named officers alleging substantially violations securities exchange act alleged putative class actions described paragraph well alleging violations section securities act failure disclose information subject matter federal trade commission ftc administrative proceeding described purporting represent class shareholders purchased shares company stock july march last business day company issued press release relating ftc administrative proceeding complaint previously filed complaints consolidated one action us district court district new jersey lead plaintiff florida state board administration appointed court july october consolidated amended complaint filed alleging violations described second sentence paragraph section claim purporting represent class shareholders purchased shares company stock may february company 's motion dismiss consolidated amended complaint denied may discovery ongoing addition lawsuits described immediately preceding paragraph two lawsuits filed us district court district new jersey two lawsuits filed new jersey state court company nominal defendant certain officers directors former director seeking damages behalf company including disgorgement trading profits made defendants allegedly obtained basis material nonpublic information complaints four lawsuits relate issues described company 's february press release allege failure disclose material information breach fiduciary duty directors one federal court lawsuits also includes allegations related investigations us attorney 's offices eastern district pennsylvania district massachusetts ftc 's administrative proceeding company lawsuit state texas warrick pharmaceuticals warrick company 's generics subsidiary described herein lawsuits shareholder derivative action purports assert claims behalf company demand made board directors decision made whether company pursue claims august plaintiffs new jersey state court shareholder derivative actions moved dismiss voluntarily complaints actions motions granted two shareholder derivative actions pending us district court district new jersey consolidated one action early stages consolidated action coordinated pretrial purposes consolidated action described immediately preceding paragraph january company received demand letter dated december law firm involved derivative actions described behalf shareholder also involved derivative actions demanding board directors bring claims behalf company based allegations substantially similar alleged derivative actions january board directors adopted board resolution establishing evaluation committee consisting three directors investigate review analyze facts circumstances surrounding allegations made demand letter consolidated amended derivative action complaint described reserving full board authority discretion exercise business judgment respect proper disposition demand committee engaged independent outside counsel advise issued report findings investigation independent directors board late october report determined shareholder demand refused finding liability part officers directors november full board adopted recommendation evaluation committee august prescription access litigation pal project bostonbased group formed litigate drug companies issued press release stating pal members filed lawsuit new jersey state court company december company served amended complaint case suit pal purports class action alleges among things company 's directtoconsumer advertising falsely depicts benefits claritin violation new jersey consumer fraud act february company filed motion dismiss case may court dismissed complaint entirety failure state claim plaintiffs appealed december pal filed class action suit federal court massachusetts company september consolidated complaint filed court result coordination multidistrict litigation panel federal court awp cases throughout country consolidated complaint alleges company warrick conspired providers defraud consumers reporting fraudulently high awps prescription medications reimbursed medicare thirdparty payers complaint seeks declaratory judgment unspecified damages including treble damages company defendant number purported nationwide state class action lawsuits plaintiffs seek refund purchase price laxatives phenylpropanolaminecontaining coughcold remedies purchased pharmaceutical manufacturers codefendants lawsuits general plaintiffs claim would purchased would paid less products known certain defects medical risks attendant use lawsuits early stages discovery plaintiffs ' theories recovery yet legally tested courts yet agreed cases go forward class actions number lawsuits involving products well recalled albuterolvancerilvancenase inhalers also filed company seeking recovery personal injuries death several lawsuits punitive damages claimed company settled california state court class action seeking refund purchase price inhalers program issuing million vouchers free inhalers plus payment attorneys ' fees court gave final approval settlement october royaltiescontract matters company party arbitration proceedings biogen inc relating among things royalty payments thesearbitrations settled october icn pharmaceuticals inc notified company intention begin alternative resolution dispute proceeding company seeking payment royalties rebetol provided company without charge reduced charge indigent patients participating schering 's commitment care program antitrust ftc matters company defendant numerous antitrust actions commenced starting state federal courts independent retail pharmacies chain retail pharmacies consumers plaintiffs allege price discrimination andor conspiracy company defendants restrain trade jointly refusing sell prescription drugs discounted prices plaintiffs company february agreed settle federal class action behalf approximately twothirds retail pharmacies united states total million paid full us district court illinois approved settlement federal class action seventh circuit court appeals dismissed appeals settlement subject review april certain plaintiffs federal class action commenced another purported class action us district court illinois company defendants settled previous federal class action complaint alleges defendants conspired implement settlement commitments following settlement discussed district court denied plaintiffs ' motion preliminary injunction hearing company either settled dismissed motion state court retailer consumer actions settlement amounts material company federal court illinois remanded conspiracy portion cases retailers opted class action back district courts filed federal court illinois jurisdiction robinsonpatman portion cases plaintiffs antitrust actions generally seek treble damages unspecified amount injunction allegedly unlawful conduct april ftc started administrative proceeding company upshersmith inc upshersmith lederle complaint alleges anticompetitive effects settlement patent lawsuits company lederle company upshersmith lawsuits settled related generic versions kdur company 's longacting potassium chloride product subject andas filed lederle upshersmith june administrative law judge overseeing case issued decision patent litigation settlements complied law respects dismissed claims company appeal decision full commission filed ftc staff currently pending outcome proceeding could result imposition injunctive administrative remedies following commencement ftc administrative proceeding alleged class action suits filed behalf direct indirect purchasers kdur company upshersmith lederle federal state courts suits allege essentially facts claim violations federal state antitrust laws well state statutory andor common law causes action pricing matters third quarter warrick sued state texas june company subsidiary schering corporation added defendants lawsuit alleges warrick supplied state false reports wholesale prices caused state pay medicaid claims prescriptions warrick 's albuterol sulfate solution inhaler higherthanjustified level state seeks damages approximately million warrick including treble damages penalties outcome litigation could result imposition fines penalties injunctive remedies company warrick defendants numerous lawsuits brought state federal courts allege company warrick reported inflated awps prescription pharmaceuticals thereby caused thirdparty payers make excess reimbursements providers actions also allege company warrick failed report accurate prices medicaid rebate program thereby underpaid rebates states actions began october brought state attorneys general private plaintiffs nonprofit organizations employee benefit funds allege violations federal state law including fraud antitrust racketeer influenced corrupt organizations act rico claims actions seek unspecified damages including treble punitive damages sec inquiry related litigation company providing information sec connection commission 's inquiry relating company 's meetings investors communications company believes complied applicable securities laws matter private plaintiffs filed several federal putative litigations company mr kogan consolidated january alleging violations sections b securities exchange act well sec regulation fair disclosure fd relating alleged disclosures made meetings investors referred preceding paragraphtax matters october irs auditors asserted reports company liable additional tax tax years reports allege two interest rate swaps company entered unrelated party recharacterized loans affiliated companies resulting additional tax income tax sought irs auditors relating recharacterization approximately million plus interest company accrued million company tax advisers believe probable irs prevail matter item submission matters vote security holders applicable executive officers registrant following information regarding executive officers included herein accordance part iii item officers elected serve one year successors shall duly elected name current position business experience age richard jay kogan present position chief executive officer chairman board chief executive officer president president chief executive officer reelected office president joseph c connors present position executive vice president general counsel jack l wyszomierski present position executive vice president chief financial officer cecil b pickett phd present position vice president president schering plough executive vice president research institute discovery research schering plough research institute richard w zahn present position vice president president schering laboratoriespresident schering laboratories geraldine u foster present position senior vice president senior vice president investor investor relations relations corporate communications daniel nichols present position senior vice president taxes mr kogan retire chief executive officer president later april name current position business experience age john p ryan present position senior vice president vice president human resources human resources scheringplough pharmaceuticals douglas j gingerella present position vice president corporate staff vice president corporate audits audits thomas h kelly present position vice president controller donald r lemma phd present position vice president corporate vice president information information technology management bristolmyers squibb chief information officer vice president chief information officer etec systems division applied materials inc director management information technologies liposome company e kevin moore present position vice president treasurer joseph j larosa present position staff vice president staff vice president commercial law secretary associate senior legal director general counsel legal director part ii item market registrant 's common equity related stockholder matters common share dividends share price data approximate number holders record set forth company 's annual report shareholders incorporated herein reference equity compensation plan information following information relates plans equity securities company may issued employees directors company plans equity securities may issued non employees except stock incentive plan predecessor plans certain stock options may transferable family members employeeoptionee related trusts plan category column column b column c number securities weightedaverage number securities remaining issued upon exercise exercise price available future issuance outstanding options outstanding options equity compensation warrants rights warrants rights plans excluding securities reflected column equity compensation plans approved security holders stock incentive plan predecessor plans equity compensation plans approved security holders directors deferred compensation na plan scheringplough ireland share purchase na scheme total plan provides annual grant shares common stock nonemployee director directors may defer awards stock units pay shares common stock deferral period ends plan permits employees reside ireland enjoy tax advantages christmas bonus pay passed trustee trustee purchases shares common stock open market allocates shares employees ' accounts irish pounds employee may deferred year employees may sell withdraw shares allocated accounts two three years item selected financial data sixyear selected financial statistical data set forth company 's annual report shareholders incorporated herein reference item management 's discussion analysis financial condition results operation management 's discussion analysis operations financial condition set forth beginning company 's annual report shareholders incorporated herein reference item quantitative qualitative disclosures market risk market risk disclosures set forth management 's discussion analysis operations financial condition beginning company 's annual report shareholders incorporated herein reference item financial statements supplementary data consolidated balance sheets december related statements consolidated income consolidated shareholders ' equity consolidated cash flows three years period ended december notes consolidated financial statements independent auditors ' report deloitte touche llp dated february unaudited quarterly data set forth beginning company 's annual report shareholders incorporated herein reference item changes disagreements accountants accounting financial disclosure applicable part iii item directors executive officers registrant information concerning directors nominees directors set forth company 's proxy statement annualmeeting shareholders april incorporated herein reference information required executive officers included part filing caption executive officers registrant item executive compensation executive compensation information set forth company 's proxy statement annual meeting shareholders april incorporated herein reference item security ownership certain beneficial owners management related stockholder matters information concerning security ownership certain beneficial owners management set forth company 's proxy statement annual meeting shareholders april incorporated herein reference item certain relationships related transactions information concerning certain relationships related transactions set forth company 's proxy statement annual meeting shareholders april incorporated herein reference item controls procedures management including chief executive officer chief financial officer evaluated company 's disclosure controls procedures within period days prior filing date concluded company 's disclosure controls procedures effective ensuring material information relating company consolidated subsidiaries made known also concluded significant changes internal controls factors could significantly affect internal controls subsequent date recent evaluation including corrective actions regard significant deficiencies material weaknesses part iv item exhibits financial statement schedules reports form k financial statements following consolidated financial statements independent auditors ' report included company 's annual report shareholders pages incorporated herein reference statements consolidated income years ended december statements consolidated cash flows years ended december consolidated balance sheets december statements consolidated shareholders ' equity years ended december notes consolidated financial statementsindependent auditors ' report financial statement schedules independent auditors ' report schedule ii valuation qualifying accounts schedules included omitted applicable required required information set forth financial statements notes thereto columns omitted schedules filed omitted information applicable financial statements fifty percent less owned companies accounted equity method omitted considered individually aggregate constitute significant subsidiary exhibits exhibit number description complete copy certificate incorporation amended currently effect incorporated reference exhibit company 's quarterly report period ended june form q certificate amendment certificate incorporation incorporated reference exhibit company 's quarterly report period ended june form q certificate amendment certificate incorporation incorporated reference exhibit company 's quarterly report period ended march form q file b complete copy bylaws amended currently effect incorporated reference exhibit company 's registration statement form file amendment bylaws effective september incorporated reference exhibit company 's quarterly report period ended september form q amendment bylaws effective april incorporated reference exhibit company 's quarterly report period ended march form q amendment bylaws effective december incorporated reference exhibit b company 's annual report file rights agreement company bank new york dated june incorporated reference exhibit form filed company june file bi form indenture company bank new york trustee filed document bii form global note filed document c form participation rights agreement company chase manhattan bank national association trustee incorporated reference exhibit company 's registration statement form amendment file exhibit description number company 's executive incentive plan amended trust related thereto plan incorporated reference exhibit company 's quarterly report period ended march form q executive incentive plan amended restated october incorporated reference exhibit company 's annual report file ii trust agreement incorporated reference exhibit company 's annual report amendment trust agreement incorporated reference exhibit b company 's quarterly report period ended march form q amended restated defined contribution trust incorporated reference exhibit aii company 's annual report file b company 's stock incentive plan amended incorporated reference exhibit company 's annual report file amendment december incorporated reference exhibit company 's annual report file amendment february filed document c company 's stock incentive plan amended incorporated reference exhibit company 's quarterly report period ended september form q amendment stock incentive plan incorporated reference exhibit company 's quarterly report period ended march form q file amendment february filed document company 's stock incentive plan incorporated reference company 's proxy statement annual meeting shareholders april amendment february filed document e retirement agreement company richard jay kogan incorporated reference exhibit form k filed november file description exhibit number e employment agreement company richard jay kogan amended incorporated reference exhibit eii company 's annual report first amendment incorporated reference exhibit b company 's quarterly report period ended june form q second amendment incorporated reference exhibit eii company 's annual report third amendment incorporated reference exhibit company 's quarterly report period ended september form q fourth amendment incorporated reference exhibit b company 's quarterly report period ended march form q fifth amendment incorporated reference exhibit eii company 's annual report sixth amendment incorporated reference exhibit company 's quarterly report period ended june form q file e ii form employment agreement company executive officers effective upon change control incorporated reference exhibit eiv company 's annual report form amendment incorporated reference exhibit company 's quarterly report period ended september form q forms amendment effective january incorporated reference exhibits e ii b company 's annual report form employment agreement company executive officers effective upon change control incorporating prior amendments january new agreements effective beginning january incorporated reference exhibit eiic company 's annual report form k file description exhibit number eiii supplement employment agreement effective upon change control described exhibit eii document index company joseph c connors incorporated reference exhibit evi company 's annual report form k file eiv supplement employment agreement effective upon change control described exhibit eii document index company jack wyszomierski incorporated reference exhibit evii company 's annual report form k file ev supplement employment agreement effective upon change control described exhibit eii document index company richard w zahn incorporated reference exhibit eviii company 's annual report form k file f amended restated directors deferred compensation plan trust related thereto incorporated reference exhibit b company 's quarterly report period ended september form q trust agreement incorporated reference exhibit company 's annual report amendment trust agreement incorporated reference exhibit b company 's quarterly report period ended march form q amended restated defined contribution trust incorporated reference exhibit aii company 's annual report file description exhibit number g supplemental executive retirement plan trust related thereto incorporated reference exhibit e company 's quarterly report period ended march form q amendment incorporated reference exhibit company 's quarterly report period ended september form q second amendment supplemental executive retirement plan effective october incorporated reference exhibit g company 's annual report amended restated trust agreement incorporated reference exhibit g company 's annual report file h amended restated directors stock award plan filed document deferred compensation plan incorporated reference exhibit b company 's quarterly report period ended september form q deferred compensation plan amended restated october incorporated reference exhibit h company 's annual report form k file j amended restated directors deferred stock equivalency program incorporated reference exhibit company 's quarterly report period ended september form q file k company 's form split dollar agreement related collateral assignment company executive officers incorporated reference exhibit l company 's annual report amendments incorporated reference exhibit g company 's quarterly report period ended march form q file exhibit description number l company 's retirement benefits equalization plan second amendment effective october incorporated reference exhibit l company 's annual report form k incorporated reference exhibit f company 's quarterly report period ended march form q amendment incorporated reference exhibit b company 's quarterly report period ended september form q file cholesterol governance agreement dated may among company merck co inc parties signatory thereto incorporated reference exhibit company 's current report form k dated october n first amendment cholesterol governance agreement dated december among company merck co inc parties signatory thereto incorporated reference exhibit company 's current report form k dated october master agreement dated december among company merck co inc parties signatory thereto incorporated reference exhibit company 's current report form k dated october p consent decree permanent injunction dated may among company parties thereto incorporated reference exhibit company 's current report form k dated may computation ratio earnings fixed charges filed document financial section company 's annual report shareholders exception portions said annual report specifically incorporated reference form k filed document report shall deemed filed part subsidiaries registrant filed document consents experts counsel filed document power attorney filed document compensatory plan contract arrangement note information omitted exhibits n pursuant request confidential treatment filed separately securities exchange commission pursuant rule b securities exchange act amended exhibits applicable copies exhibits furnished upon request b reports form k threemonth period ended december company furnished three current reports form k report filed october item events regulation fd disclosure item financialstatements exhibits report filed october item financial statements exhibits item regulation fd disclosure report filed november item events regulation fd disclosure item financial statements exhibits signatures pursuant requirements section securities exchange act registrant duly caused report signed behalf undersigned thereunto duly authorized scheringplough corporation registrant date march thomas h kelly thomas h kelly vice president controller pursuant requirements securities exchange act report signed following persons behalf registrant capacities date indicated richard jay kogan richard jay kogan carl e mundy jr chief executive officer director president director jack l wyszomierski jack l wyszomierski richard de j osborne executive vice president chairman board director chief financial officer thomas h kelly thomas h kelly patricia f russo vice president controller director principal accounting officer hans w becherer kathryn c turner director director david h komansky robert f w van oordt director director eugene r mcgrath arthur f weinbach director director donald l miller director sthomas h kelly date march thomas h kelly attorneyinfact certification jack l wyszomierski executive vice president chief financial officer certify reviewed annual report scheringplough corporation registrant based knowledge annual report contain untrue statement material fact omit state material fact necessary make statements made light circumstances statements made misleading respect period covered annual report based knowledge financial statements financial information included annual report fairly present material respects financial condition results operations cash flows registrant periods presented annual report registrant 's certifying officers responsible establishing maintaining disclosure controls procedures defined exchange act rules registrant designed disclosure controls procedures ensure material information relating registrant including consolidated subsidiaries made known us others within entities particularly period annualreport prepared b evaluated effectiveness registrant 's disclosure controls procedures date within days prior filing date annual report evaluation date c presented annual report conclusions effectiveness disclosure controls procedures based evaluation evaluation date registrant 's certifying officers disclosed based recent evaluation registrant 's auditors audit committee registrant 's board directors persons performing equivalent functions significant deficiencies design operation internal controls could adversely affect registrant 's ability record process summarize report financial data identified registrant 's auditors material weaknesses internal controls b fraud whether material involves management employees significant role registrant 's internal controls registrant 's certifying officers indicated annual report whether significant changes internal controls factors could significantly affect internal controls subsequent date recent evaluation including corrective actions regard significant deficiencies material weaknesses date march jack l wyszomierski jack l wyszomierski executive vice president chief financial officer certification richard jay kogan chief executive officer president certify reviewed annual report scheringplough corporation registrant based knowledge annual report contain untrue statement material fact omit state material fact necessary make statements made light circumstances statements made misleading respect period covered annual report based knowledge financial statements financial information included annual report fairly present material respects financial condition results operations cash flows registrant periods presented annual report registrant 's certifying officers responsible establishing maintaining disclosure controls procedures defined exchange act rules registrant designed disclosure controls procedures ensure material information relating registrant including consolidated subsidiaries made known us others within entities particularly period annual report prepared b evaluated effectiveness registrant 's disclosure controls procedures date within days prior filing date annual report evaluation date c presented annual report conclusions effectiveness disclosure controls procedures based evaluation evaluation date registrant 's certifying officers disclosed based recent evaluation registrant 's auditors audit committee registrant 's board directors persons performing equivalent functions significant deficiencies design operation internal controls could adversely affect registrant 's ability record process summarize report financial data identified registrant 's auditors material weaknesses internal controls b fraud whether material involves management employees significant role registrant 's internal controls registrant 's certifying officers indicated annual report whether significant changes ininternal controls factors could significantly affect internal controls subsequent date recent evaluation including corrective actions regard significant deficiencies material weaknesses date march richard jay kogan richard jay kogan chief executive officer president certification jack l wyszomierski executive vice president chief financial officer scheringplough corporation certify pursuant section sarbanesoxley act annual report year ended december annual report statement accompanies fully complies requirements section securities exchange act usc information contained annual report fairly presents material respects financial condition results operations scheringplough corporation certificate furnished solely purposes section filed part annual report dated march jack l wyszomierski jack l wyszomierski executive vice president chief financial officer certification richard jay kogan chief executive officer president scheringplough corporation certify pursuant section sarbanesoxley act annual report year ended december annual report statement accompanies fully complies requirements section securities exchange act usc information contained annual report fairly presents material respects financial condition results operations scheringplough corporation certificate furnished solely purposes section filed part annual report dated march richard jay kogan richard jay kogan chief executive officer presidentindependent auditors ' report scheringplough corporation directors shareholders audited consolidated financial statements scheringplough corporation subsidiaries december three years period ended december issued report thereon dated february financial statements report included annual report shareholders incorporated herein reference audits also included financial statement schedule scheringplough corporation subsidiaries listed item financial statement schedule responsibility company 's management responsibility express opinion based audits opinion financial statement schedule considered relation basic consolidated financial statements taken whole presents fairly material respects information set forth therein sdeloitte touche llp parsippany new jersey february schedule ii scheringplough corporation subsidiaries valuation qualifying accounts years ended december dollars millions valuation qualifying accounts deducted assets apply allowances accounts receivable reserve reserve reserve doubtful cash claims accounts discounts total balance beginning year additions charged costs expenses deductions reserves effects foreign exchange balance end year balance beginning year additions charged costs expenses deductions reserves effects foreign exchange balance end year balance beginning year additions charged costs expenses deductions reserves effects foreign exchange balance end year